Google Continues To Build Upon Its Life Sciences Ecosystem

Google has a mission to organize the worlds information and make it accessible to everyone. The companyis mostly known for its search engine and the largest mobile operating system, but you may not be aware that Google is also heavily involved in the life sciences sector. Google has invested in a number of biotech and life science companies through its venture capital arm, Google Ventures.

Lift Labs

Yesterday, Google acquired Lift Labs. Lift Labs is a company that has built a high-tech device handle, which can stabilize what is being held using an attachable spoon or fork. This type of device benefits someone that has Parkinsons Disease or Essential tremor (ET). The Lift Labs team is joining the Life Sciences division at Google[x], which is a skunkworks lab led by Google co-founder Sergey Brin.

DNAnexus

DNAnexus is a DNA sequencing data software company that works with several genome sequencing organizations to better understand human genetics contributing to heart disease and aging.Last year, DNAnexus partnered with Baylor College of Medicine to process 3,751 whole human genomes and 10,771 exomes. DNAnexus uses Amazon Web Services cloud computing to sequence DNA data and store it.GoogleVentures invested in DNAnexus$15 million Series B and $15 million Series C round of funding.

Rani Therapeutics

Google Ventures participated in an undisclosed Series B round for Rani Therapeutics in August 2013. Rani Therapeutics is working on developing technology for the oral delivery of large drug molecules, which are delivered through injections.Rani Therapeutics is currently in pre-clinical studies and demonstrated over 50% bioavailability.

SynapDx

SynapDx is a company that provides laboratory testing services to physicians who work with children that have development disorders. The goal is to enable earlier detection of autism. In July 2013, Google participated in a $15.4 million round of funding for SynapDx.

One Medical Group

Read the original here:

Google Continues To Build Upon Its Life Sciences Ecosystem

Center to Find Drug Combinations that Reduce Side Effects

Contact Information

Available for logged-in reporters only

Newswise (New York, NY Sept. 11, 2014) A research team from the Icahn School of Medicine at Mount Sinai today received a $12 million grant from the National Institutes of Health to create a center that will screen massive data sets for new uses of existing drugs, and confirm them in human cell tests. The centers first mission will be to find FDA-approved drugs that reduce side effects when paired with hundreds of leading drugs against common, deadly diseases.

With advances in inexpensive computing power, and stored data collections becoming truly massive in the era of big data, researchers are just now able to design algorithms and models that pull previously unrecognized disease and drug treatment patterns from databases. These computational patterns are predictive, and researchers can validate them with experiments.

The goal of our new center is to detect changes made in human heart, liver and nerve cells as otherwise useful drugs cause side effects, and to find the combinations of existing drugs that reduce these side effects, said Ravi Iyengar, PhD, the Dorothy H. and Lewis Rosenstiel Professor in the Department of Pharmacology and Systems Therapeutics within the Icahn School of Medicine at Mount Sinai, and the lead investigator for the center grant.

Our center embodies a third way to reduce the side effects that limit the use of so many treatments, along with two traditional approaches: fine-tuning a drugs chemical structure or tailoring its use for each individuals genetics, he added.

Hidden Signatures The new grant will fund a Drug Toxicity Signature Generation Center at Mount Sinai as part the NIH Common Funds LINCS program, the Library of Integrated Network-based Cellular Signatures program. Each signature is a confirmed set of genetic and protein responses within a type of cell to a drug or drug combination.

The team will find such signatures by combining high-throughput experiments on cell responses to drugs with statistical analyses of side effect, gene and protein interaction databases. Interestingly, the team starts with stem cells and then converts them into the heart, liver and nerve cells used in the experiments. The new centers goal is to generate 2,000 signatures per year for further testing.

To anchor the signatures to human diseases and treatments, the team will search the U.S. Food and Drug Administrations Adverse Event Reporting System (FAERS) database to find cases where adding a second drug reduced the side effects associated with a commonly used primary treatment. FAERS has for decades collected such data from individuals, health professionals, drug companies and hospitals, and the millions of records on patients taking multiple drugs now in this public database are free and open to all researchers for analysis.

To translate FAERS-generated drug combinations that reduce toxicity into networks of mechanism-based cell response signatures, the team will then run the experimental results through other databases, including NIH databases of human DNA sequences and interactions between proteins. These networks will be filtered using sophisticated modeling techniques to increase the reliability of the signatures. The most promising signatures can then form the basis for targeted animal and human clinical studies on drug repurposing.

More:

Center to Find Drug Combinations that Reduce Side Effects

Seven researchers awarded for work presented at yeast genetics conference

PUBLIC RELEASE DATE:

8-Sep-2014

Contact: Raeka Aiyar, Ph.D. raeka.aiyar@gmail.com 202-412-1120 Genetics Society of America

BETHESDA, MD The Genetics Society of America (GSA) and the yeast genetics research community are pleased to announce the winners of the GSA poster awards at the 2014 Yeast Genetics Meeting, which took place in Seattle, WA, July 29August 3, 2014. These awards were made to undergraduate, graduate, and postdoctoral scientists in recognition of the research they presented at the conference. Their projects examined the molecular basis of several processes governing the inheritance of traits using yeast as a model organism.

"The breadth and depth of the science presented at this meeting was impressive and inspiring," remarked Adam Fagen, PhD, GSA's executive director. "We are very proud to see these significant contributions to genetics research from these early career scientists and look forward to following their continued success throughout their careers."

Nearly 400 research posters were presented at the meeting, and the winning posters were selected by a panel of leading yeast genetics researchers. The winners of the 2014 Yeast Genetics Meeting GSA Poster Awards are as follows:

First Place: Joseph Sanchez (PhD student, University of Washington) Advisor: Dr. Bonny Brewer Title:: "The human Meier-Gorlin Syndrome mutation in ORC4 reduces replication initiation and rDNA copy number in Saccharomyces cerevisiae"

Second Place: Jinglin Xie (PhD student, University of Toronto) Advisor: Dr. Leah Cowen Title: "Dissecting the role of calcineurin and protein kinase C signalling in Hsp90-dependent caspofungin tolerance"

Third Place: Mark Rutledge (PhD student, Princeton University) Advisor: Dr. Jim Broach Title: "Chromatin organization in quiescent yeast"

Fourth Place: Erica Hildebrand (PhD student, Fred Hutchinson Research Center) Advisor: Dr. Susan Biggins Title: "Regulation of centromeric nucleosome localization by the E3 ubiquitin ligase Psh1"

See the rest here:

Seven researchers awarded for work presented at yeast genetics conference

23andMe aims to be Google for genetic research

MOUNTAIN VIEW -- In less than a decade, biotech company 23andMe has turned a refrigerator full of spit into one of the largest databases of personal genetics information in the world.

The brainchild of Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe began in 2006 as a startup mailing DNA testing kits to customers' front doors and asking them to mail back a vial of saliva. Eight years later, the company is the gatekeeper of a database of hundreds of thousands of people's DNA -- a self-described Google for genetics information.

"It's actually bigger than anything else I can think of, way bigger," said Lisa Brooks, program director of the National Human Genome Research Institute, part of the National Institutes of Health.

23andMe has begun selling that genetics data to researchers and pharmaceutical companies to conduct large-scale medical studies, making it an emerging leader in a largely underexplored, and at times hotly debated, area of scientific research. In the last couple of months, 23andMe has announced a joint effort with Pfizer to research inflammatory bowel disease, released findings from a joint study of more than 100,000 people that made new discoveries on Parkinson's disease, and received a $1.4 million grant from the NIH.

But as the guardian of a very lucrative set of data -- the accuracy of which has come under question -- critics say the Mountain View company also may pose a threat to consumers' privacy.

Most medical studies take months or years to solicit enough volunteers. But 23andMe puts the genetic information of 700,000 people at researchers' fingertips, allowing medical studies to be fast-tracked and new treatments to make their way into hospitals sooner, experts say, giving patients with chronic diseases a better quality of life.

"Instead of actually having to do clinical trials the old-fashioned way, we can enable researchers to get their answers instantaneously," Wojcicki said in an interview with this newspaper. "And they pay us for that."

But some experts worry 23andMe users have no idea where their own genetic information will end up. Because the company is relying on data sales to become profitable -- selling $99 home genetic testing kits doesn't pull in the big-dollar revenue -- 23andMe may disseminate consumers' genetic information not only to government agencies and research institutions, say legal and bioethics experts, but also to big pharmaceutical companies, marketers and advertisers.

"There are a lot of people who would want to use that data. There's a lot of money potentially locked up in that data," said Charles Seife, a professor at New York University and longtime science writer.

Indeed, in a 2013 interview with The New York Times, Wojcicki said, "I remember in the early days of Google, Larry (Page) would say, 'I just want the world's data on my laptop.' I feel the same way about health care. I want the world's data accessible."

See more here:

23andMe aims to be Google for genetic research

Court dismisses second appeal to overturn ruling on corporate human gene patenting

ABC Yvonne D'Arcy has lost her second appeal to overturn a court ruling on human gene patening.

The full bench of the Federal Court has thrown out an appeal against a ruling allowing private companies to patent human genes.

Last year breast cancer survivor Yvonne D'Arcy lodged an appeal after two bio-tech companies were granted the patent to a hereditary gene associated with an increased risk of cancer.

A court had previously ruled the patent applied because the genetic material needed to be extracted from the body to be tested.

Ms D'Arcy, from Brisbane, argued the genes existed in nature, so were discovered rather than invented.

She said she launched the case even though she herself did not have the BRCA1 gene.

Her case was against US-based company Myriad Genetics and Melbourne-based company Genetic Technologies.

The full bench of the Federal Court in Sydney has today dismissed her second appeal in the case, stating that "expressions such as the work of nature or the laws of nature are unhelpful when dealing with claims of a kind in this case".

"One may distinguish between discovery of a piece of abstract information without suggestion of a practical application to a useful end, on the one hand, and a useful result produced by doing something which has not been done by that procedure before, on the other," the five-judge panel said.

Ms D'Arcy's lawyer Rebecca Gilsenen from Maurice Blackburn said the judgment was disappointing.

Original post:

Court dismisses second appeal to overturn ruling on corporate human gene patenting

Extinctions During Human Era Worse Than Thought

David Orenstein, Brown University

The gravity of the worlds current extinction rate becomes clearer upon knowing what it was before people came along. A new estimate finds that species die off as much as 1,000 times more frequently nowadays than they used to. Thats 10 times worse than the old estimate of 100 times.

Its hard to comprehend how bad the current rate of species extinction around the world has become without knowing what it was before people came along. The newest estimate is that the pre-human rate was 10 times lower than scientists had thought, which means that the current level is 10 times worse.

Extinctions are about 1,000 times more frequent now than in the 60 million years before people came along. The explanation from lead author Jurriaan de Vos, a Brown University postdoctoral researcher, senior author Stuart Pimm, a Duke University professor, and their team appears online in the journal Conservation Biology.

This reinforces the urgency to conserve what is left and to try to reduce our impacts, said de Vos, who began the work while at the University of Zurich. It was very, very different before humans entered the scene.

In absolute, albeit rough, terms the paper calculates a normal background rate of extinction of 0.1 extinctions per million species per year. That revises the figure of 1 extinction per million species per year that Pimm estimated in prior work in the 1990s. By contrast, the current extinction rate is more on the order of 100 extinctions per million species per year.

Orders of magnitude, rather than precise numbers are about the best any method can do for a global extinction rate, de Vos said. Thats just being honest about the uncertainty there is in these type of analyses.

From fossils to genetics

The new estimate improves markedly on prior ones mostly because it goes beyond the fossil record. Fossils are helpful sources of information, but their shortcomings include disproportionate representation of hard-bodied sea animals and the problem that they often only allow identification of the animal or plants genus, but not its exact species.

What the fossils do show clearly is that apart from a few cataclysms over geological periods such as the one that eliminated the dinosaurs biodiversity has slowly increased.

Continued here:

Extinctions During Human Era Worse Than Thought

Human vaccine trials to start

STORY HIGHLIGHTS

(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.

After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).

It will be the first test of this type of Ebola vaccine in humans.

The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Go here to see the original:

Human vaccine trials to start

Human trial of Ebola vaccine begins

STORY HIGHLIGHTS

(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.

After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).

It will be the first test of this type of Ebola vaccine in humans.

The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Ebola outbreak in Africa

Read the rest here:

Human trial of Ebola vaccine begins

ASHG and NHGRI award genetics and public policy fellowship

PUBLIC RELEASE DATE:

2-Sep-2014

Contact: Nalini Padmanabhan press@ashg.org 301-634-7346 American Society of Human Genetics

BETHESDA, MD - The American Society of Human Genetics (ASHG) and the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, have named Katherine D. Blizinsky, PhD, a neuroscientist at Northwestern University in Chicago, the newest ASHG/NHGRI Genetics and Public Policy Fellow. The 16-month appointment begins today.

The Genetics and Public Policy Fellowship is intended to help early-career genetics professionals develop and implement genetics-related health and research policy at a national level. Fellows in the program gain policy experience in diverse settings by completing rotations in the non-profit science advocacy sector at ASHG, in the executive branch at NHGRI, and in the legislative branch as a staff member on Capitol Hill. ASHG and NHGRI have jointly sponsored the fellowship since 2002.

Dr. Blizinsky has served in various genetics research roles since 2008, studying varying topics in the areas of psychiatric neurogenetics and genomics, gene-environment coevolution of psychiatric susceptibility, and imaging genetics of neurological and psychiatric conditions. She received the Sage Bionetworks Young Investigator Award in 2012 and co-founded Science Policy Initiative Northwestern, an organization that fosters science policy dialogue in the university community through panel discussions, lectures, and interactive debates.

"With her diversity of experience inside and outside the genetics laboratory, Dr. Blizinsky will bring her practical knowledge of genetics research to settings where the potential impact of that research can be more fully realized and disseminated," said Joseph McInerney, MA, MS, executive vice president of ASHG.

"Our fellows have gone on to work at a wide variety of influential organizations," said Derek Scholes, PhD, chief of NHGRI's Policy and Program Analysis Branch. "We're confident that this fellowship will provide a good foundation for Dr. Blizinsky's career in health policy."

###

Follow this link:

ASHG and NHGRI award genetics and public policy fellowship

Human trial of Ebola vaccine begins this week

The human trial of an experimental Ebolavaccine will begin this week, according to the National Institutes of Health, United States of America.

In a statement on Tuesday, the Director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, said the US Food and Drug Administration had given the researchers at the institute the approval to begin the human safety trial.

The experimental vaccine, developed by the pharmaceutical company, GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged between 18 and 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.

The vaccine will be administered to volunteers by an injection in the deltoid muscle of their arm, first in a lower dose; then later, in a higher dose after the safety of the vaccine has been determined.

Some of the preclinical studies that are normally done on these types of vaccines were waived by the FDA during the expedited review, Fauci said. So we want to take extra special care that we go slowly with the dosing.

The vaccine did extremely well in earlier trials with chimpanzees, Fauci told the AFP on Tuesday.

He noted that the method being used to prompt an immune response to Ebola could not cause a healthy individual to become infected with the virus.

Still, he said, I have been fooled enough in my many years of experience you really cant predict what you will see (in humans).

According to the NIH, the vaccine will also be tested on healthy volunteers in the United Kingdom, Gambia and Mali, once details are finalised with health officials in those country.

Meanwhile, officials from the Centres for Disease Control and Prevention, US, have said that the human trials of Ebola vaccines cannot currently be done in the four countries affected by the recent outbreak Guinea, Sierra Leone, Liberia and Nigeria due to the conditions of existing health care infrastructure in these countries.

Originally posted here:

Human trial of Ebola vaccine begins this week

ASHG and NHGRI award first genetics and education fellowship

PUBLIC RELEASE DATE:

2-Sep-2014

Contact: Nalini Padmanabhan press@ashg.org 301-634-7346 American Society of Human Genetics

BETHESDA, MD The American Society of Human Genetics (ASHG) and the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, have named Elizabeth P. Tuck, MA, Upper School Science Teacher at The Wellington School in Columbus, Ohio, the first ASHG/NHGRI Genetics and Education Fellow. The 16-month appointment begins today.

The Genetics and Education Fellowship is intended to help early-career genetics professionals expand their skills, experience, and network to prepare for a career in genetics education. Fellows in the program will complete rotations at both sponsoring organizations in areas that may include curriculum development, education research, faculty professional development, public education and outreach, and science education policy.

Ms. Tuck has served in various roles related to science education since 2008, including teaching high school biology, developing biotechnology and neuroscience curricula for underserved youth, and organizing science caf events for teenagers. She has also conducted laboratory research at the undergraduate and graduate levels, focusing on the genetics and cellular mechanisms underlying neurological diseases.

"With her background in both laboratory genetics research and science education, Ms. Tuck is exceptionally well-qualified to take advantage of the opportunities this fellowship provides," said Michael J. Dougherty, PhD, ASHG's Director of Education. "We are excited to launch this new program with a fellow who has worked in varied settings and who can effectively combine diverse perspectives to identify and address challenges in genetics education."

The ASHG/NHGRI Genetics and Education Fellowship is modeled after the ASHG/NHGRI Genetics and Public Policy Fellowship, which ASHG and NHGRI have jointly sponsored since 2002.

"NHGRI is pleased with the implementation of the new fellowship program. Ms. Tuck will be our first fellow and we could not be more delighted. We anticipate her helping to make the education fellowship program as successful as the long-standing ASHG-NHGRI policy fellowship program," said Vence L. Bonham, Jr., JD, chief of the Education and Community Involvement Branch at NHGRI.

"The Genetics and Public Policy Fellowship has been successful in helping to train genetics professionals who currently occupy significant positions in policy and advocacy organizations and in government. We hope the new program has a similar impact," added Joseph D. McInerney, MA, MS, Executive Vice President of ASHG.

Here is the original post:

ASHG and NHGRI award first genetics and education fellowship

Human Ebola vaccine trial to start

A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.

After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).

It will be the first test of this type of Ebola vaccine in humans.

The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.

The vaccine will be administered to volunteers by an injection in the deltoid muscle of their arm, first in a lower dose, then later in a higher dose after the safety of the vaccine has been determined.

Some of the preclinical studies that are normally done on these types of vaccines were waived by the FDA during the expedited review, Fauci said, so "we want to take extra special care that we go slowly with the dosing."

The vaccine did extremely well in earlier trials with chimpanzees, Fauci said. He noted that the method being used to prompt an immune response to Ebola cannot cause a healthy individual to become infected with the virus.

Still, he said, "I have been fooled enough in my many years of experience... you really can't predict what you will see (in humans)."

According to the NIH, the vaccine will also be tested on healthy volunteers in the United Kingdom, Gambia and Mali, once details are finalized with health officials in those countries.

Trials cannot currently be done in the four countries affected by the recent outbreak -- Guinea, Sierra Leone, Liberia and Nigeria -- because the existing health care infrastructure wouldn't support them, Fauci said. Gambia and Mali were selected because the NIH has "long-standing collaborative relationships" with researchers in those countries.

View post:

Human Ebola vaccine trial to start

Human trial of experimental Ebola vaccine begins this week

NEWS

Posted YESTERDAY, 5:41 AM Updated YESTERDAY, 5:42 AM

A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.

After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

It will be the first test of this type of Ebola vaccine in humans.

The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.

The vaccine will be administered to volunteers by an injection in the deltoid muscle of their arm, first in a lower dose, then later in a higher dose after the safety of the vaccine has been determined.

Some of the preclinical studies that are normally done on these types of vaccines were waived by the FDA during the expedited review, Fauci said, so "we want to take extra special care that we go slowly with the dosing."

The vaccine did extremely well in earlier trials with chimpanzees, Fauci said. He noted that the method being used to prompt an immune response to Ebola cannot cause a healthy individual to become infected with the virus.

Still, he said, "I have been fooled enough in my many years of experience... you really can't predict what you will see (in humans)."

Excerpt from:

Human trial of experimental Ebola vaccine begins this week

MARC travel awards announced for: American Society of Human Genetics 2014 Annual Meeting

PUBLIC RELEASE DATE:

28-Aug-2014

Contact: Kelly Husser khusser@faseb.org 301-634-7109 Federation of American Societies for Experimental Biology

Bethesda, MD FASEB MARC (Maximizing Access to Research Careers) Program has announced the travel award recipients for the American Society of Human Genetics from October 18 22, 2014 in San Diego, California. These awards are meant to promote the entry of students, post doctorates and scientists from underrepresented groups into the mainstream of the basic science community and to encourage the participation of young scientists at the American Society of Human Genetics. This year MARC conferred 16 awards totaling $29,600.

The FASEB MARC Program is funded by a grant from the National Institute of General Medical Sciences, National Institutes of Health. A primary goal of the MARC Program is to increase the number and competitiveness of underrepresented groups engaged in biomedical and behavioral research. The following participants have been selected to receive a FASEB MARC Travel Award:

POSTER/ORAL PRESENTER (FASEB MARC PROGRAM)

FACULTY/MENTOR & STUDENT/MENTEE (FASEB MARC PROGRAM)

###

FASEB is composed of 27 societies with more than 120,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

View post:

MARC travel awards announced for: American Society of Human Genetics 2014 Annual Meeting

Scientists looking across human, fly and worm genomes find shared biology

PUBLIC RELEASE DATE:

27-Aug-2014

Contact: Steve Benowitz steven.benowitz@nih.gov 301-451-8325 NIH/National Human Genome Research Institute

Researchers analyzing human, fly, and worm genomes have found that these species have a number of key genomic processes in common, reflecting their shared ancestry. The findings, appearing Aug. 28, 2014, in the journal Nature, offer insights into embryonic development, gene regulation and other biological processes vital to understanding human biology and disease.

The studies highlight the data generated by the modENCODE Project and the ENCODE Project, both supported by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. Integrating data from the three species, the model organism ENCyclopedia Of DNA Elements (modENCODE) Consortium studied how gene expression patterns and regulatory proteins that help determine cell fate often share common features. Investigators also detailed the similar ways in which the three species use protein packaging to compact DNA into the cell nucleus and to regulate genome function by controlling access to DNA.

Launched in 2007, the goal of modENCODE is to create a comprehensive catalog of functional elements in the fruit fly and roundworm genomes for use by the research community. Such elements include genes that code for proteins, non-protein-coding genes and regulatory elements that control gene expression. The current work builds on initial catalogs published in 2010. The modENCODE projects complement the work being done by the ENCyclopedia Of DNA Elements (ENCODE) Project, which is building a comprehensive catalog of functional elements in the human and mouse genomes.

"The modENCODE investigators have provided a valuable resource for researchers worldwide," said NHGRI Director Eric Green, M.D., Ph.D. "The insights gained about the workings of model organisms' genomes greatly help to inform our understanding of human biology."

"One way to describe and understand the human genome is through comparative genomics and studying model organisms," said Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics at Yale University in New Haven, Connecticut, and the lead author on one of the papers. "The special thing about the worm and fly is that they are very distant from humans evolutionarily, so finding something conserved across all three human, fly and worm tells us it is a very ancient, fundamental process."

In one study, scientists led by Dr. Gerstein and others, analyzed human, fly and worm transcriptomes, the collection of gene transcripts (or readouts) in a genome. They used large amounts of gene expression data generated in the ENCODE and modENCODE projects including more than 67 billion gene sequence readouts to discover gene expression patterns shared by all three species, particularly for developmental genes.

Investigators showed that the ways in which DNA is packaged in the cell are similar in many respects, and, in many cases, the species share programs for turning on and off genes in a coordinated manner. More specifically, they used gene expression patterns to match the stages of worm and fly development and found sets of genes that parallel each other in their usage. They also found the genes specifically expressed in the worm and fly embryos are re-expressed in the fly pupae, the stage between larva and adult.

See original here:

Scientists looking across human, fly and worm genomes find shared biology

Shared biology in human, fly and worm genomes: Powerful commonalities in biological activity, regulation

Researchers analyzing human, fly, and worm genomes have found that these species have a number of key genomic processes in common, reflecting their shared ancestry. The findings, appearing Aug. 28, 2014, in the journal Nature, offer insights into embryonic development, gene regulation and other biological processes vital to understanding human biology and disease.

The studies highlight the data generated by the modENCODE Project and the ENCODE Project, both supported by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. Integrating data from the three species, the model organism ENCyclopedia Of DNA Elements (modENCODE) Consortium studied how gene expression patterns and regulatory proteins that help determine cell fate often share common features. Investigators also detailed the similar ways in which the three species use protein packaging to compact DNA into the cell nucleus and to regulate genome function by controlling access to DNA.

Launched in 2007, the goal of modENCODE is to create a comprehensive catalog of functional elements in the fruit fly and roundworm genomes for use by the research community. Such elements include genes that code for proteins, non-protein-coding genes and regulatory elements that control gene expression. The current work builds on initial catalogs published in 2010. The modENCODE projects complement the work being done by the ENCyclopedia Of DNA Elements (ENCODE) Project, which is building a comprehensive catalog of functional elements in the human and mouse genomes.

"The modENCODE investigators have provided a valuable resource for researchers worldwide," said NHGRI Director Eric Green, M.D., Ph.D. "The insights gained about the workings of model organisms' genomes greatly help to inform our understanding of human biology."

"One way to describe and understand the human genome is through comparative genomics and studying model organisms," said Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics at Yale University in New Haven, Connecticut, and the lead author on one of the papers. "The special thing about the worm and fly is that they are very distant from humans evolutionarily, so finding something conserved across all three -- human, fly and worm -- tells us it is a very ancient, fundamental process."

In one study, scientists led by Dr. Gerstein and others, analyzed human, fly and worm transcriptomes, the collection of gene transcripts (or readouts) in a genome. They used large amounts of gene expression data generated in the ENCODE and modENCODE projects -- including more than 67 billion gene sequence readouts -- to discover gene expression patterns shared by all three species, particularly for developmental genes.

Investigators showed that the ways in which DNA is packaged in the cell are similar in many respects, and, in many cases, the species share programs for turning on and off genes in a coordinated manner. More specifically, they used gene expression patterns to match the stages of worm and fly development and found sets of genes that parallel each other in their usage. They also found the genes specifically expressed in the worm and fly embryos are re-expressed in the fly pupae, the stage between larva and adult.

The researchers found that in all three organisms, the gene expression levels for both protein-coding and non-protein-coding genes could be quantitatively predicted from chromatin features at the promoters of genes. A gene's promoter tells the cell's machinery where to begin copying DNA into RNA, which can be used to make proteins. DNA is packaged into chromatin in cells, and changes in this packaging can regulate gene function.

"Our findings open whole new worlds for understanding gene expression and how we think about the role of transcription," said co-senior author Susan Celniker, Ph.D., Head, Department of Genome Dynamics, Lawrence Berkeley National Laboratory, Berkeley, California. "modENCODE has been transformative," she added. "It has helped set the standard for the types of data that should be generated and catalogued."

Another group of scientists investigated how chromatin is organized and how it influences gene regulation in the three species. Using both modENCODE and ENCODE data, scientists compared patterns of modifications in chromatin that are needed for the cell to access the DNA inside, and the changes in DNA replication patterns as a result of these modifications. The investigators discovered that many features of chromatin were similar in all three species.

Follow this link:

Shared biology in human, fly and worm genomes: Powerful commonalities in biological activity, regulation

GSK/NIAID Ebola Vaccines To Enter US, UK Human Safety Trials

The Wellcome Trust, the Medical Research Council (MRC), and the UK Department for International Development (DFID) have announced this morning that an Ebola vaccine developed in the U.S. will enter human safety trials in the UK as early as September. The consortium is devoting 2.8 million to the effort.

Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), an arm of the U.S. National Institutes of Health, held a press conference this morning to discuss the specifics about the U.S. vaccine. The FDA has given the green light to begin testing here.

The vaccine was designed by Nancy J. Sullivan, Ph.D., chief of the Biodefense Research Section in NIAIDs Vaccine Research Center (VRC). She worked with other collaborators in the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) and scientists at the Swiss-Italian biotechnology company,Okairos, acquired byGlaxoSmithKlinein May, 2013.

Ebola virus particles, colored digitally, emerging from a type of monkey epithelial cell line (Vero) grown in the laboratory. Credit: CDC Public Health Image Library

The GSK/NIAID vaccine has been designed to produce a protective immune reaction toward the surface protein on the Zaire Ebola and Sudan Ebola viruses, a protein required for the virus to normally infect humans. Because its directed at two versions of the viral protein, its called a bivalent vaccine.

In science, you never know

While the vaccine has proven to protect non-human primates from Ebola infection and produced high levels of immunogenic responses, the phase 1 trials are being conducted to ensure that any untoward reactions in humans are detected and the production of protective antibodies proceeds as observed in non-human primates.

NIAID will be starting with typical caution for the first time a vaccine is tested in healthy human volunteers. The trial, termed VRC 207, will ultimately enroll 20 healthy, adult human volunteers (age 18 to 50 years) and evaluate the safety of the virus nine times over a 48-week period and, said Fauci, whether it generates an immune response in healthy adults that, based on our animal studies, could predict effectiveness in preventing the acquisition of Ebola infection.

The volunteers will be split into two groups to receive a high or low dose of the vaccine. The trial will be staged so that small groups of volunteers receive the vaccine at a time, with the first three volunteers to be dosed starting next week at the NIH Clinical Research Center in Bethesda, Maryland. Those three volunteers will be followed for three days before any other volunteers are injected.

We expect to be able to report initial safety and immunogenicity data from this study by the end of this calendar year, said Dr. Fauci.

Read the original here:

GSK/NIAID Ebola Vaccines To Enter US, UK Human Safety Trials